{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-21-023269","form_type":"8-K","ticker":"ABEO","cik":"0000318306","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2021-09-21T23:59:59+00:00","discovered_at":"2026-05-14T18:04:20.331903+00:00","generated_at":"2026-06-29T02:26:40.250918+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Abeona appoints new CEO, chairman; prepares for two BLA submissions","bullets":["Michael Amoroso resigns as President/CEO effective Oct 14, 2021; appointed Chairman Oct 15.","Steven Rouhandeh retires as Chairman and board member effective Oct 14, 2021.","Vishwas Seshadri appointed President/CEO and director effective Oct 15; base salary $500K plus equity.","Promotions: Brendan O'Malley to General Counsel, Brian Kevany to CTO; adds regulatory veterans Carl Denny and Kate Imhoff.","Leadership changes aim to support two BLA submissions for EB-101 (RDEB) and ABO-102 (MPS IIIA)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-21-023269","json":"https://secwatch.observer/filing/0001493152-21-023269.json","markdown":"https://secwatch.observer/filing/0001493152-21-023269.md","text":"https://secwatch.observer/filing/0001493152-21-023269.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/318306/000149315221023269/0001493152-21-023269-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/318306/000149315221023269/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T02:26:40.250918+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"23b5ef9e2d","claim":"Steven Rouhandeh departed as Chairman of the Board at ABEONA THERAPEUTICS INC..","evidence_excerpt":"Steven Rouhandeh, Chairman of the Board, notified the Company of his retirement and resignation as a member of the Board effective October 14.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315221023269/0001493152-21-023269-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retired and resigned"},{"label":"Role","value":"Chairman of the Board"}],"fact_type":"executive_change"},{"claim_id":"2de40d7fa2","claim":"Vishwas Seshadri was appointed as President and Chief Executive Officer and director at ABEONA THERAPEUTICS INC..","evidence_excerpt":"the Board appointed Vishwas Seshadri, Ph.D., M.B.A., as President and Chief Executive Officer and director effective October 15, 2021.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315221023269/0001493152-21-023269-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer and director"}],"fact_type":"executive_change"},{"claim_id":"7dfa531b7b","claim":"Michael Amoroso resigned as President and Chief Executive Officer at ABEONA THERAPEUTICS INC..","evidence_excerpt":"Michael Amoroso, President and Chief Executive Officer of Abeona Therapeutics Inc. (the “Company”), and a member of the Board of Directors (the “Board”), notified the Company of his resignation as President and Chief Executive Officer effective October 14, 2021.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315221023269/0001493152-21-023269-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"cccf43dbdc","claim":"Michael Amoroso was appointed as Chairman of the Board at ABEONA THERAPEUTICS INC..","evidence_excerpt":"the Board voted unanimously to appoint Mr. Amoroso Chairman of the Board effective October 15.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315221023269/0001493152-21-023269-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chairman of the Board"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}